Literature DB >> 12548138

Acyl glucuronide drug metabolites: toxicological and analytical implications.

Maria Shipkova1, Victor William Armstrong, Michael Oellerich, Eberhard Wieland.   

Abstract

Although glucuronidation is generally considered a detoxification route of drug metabolism, the chemical reactivity of acyl glucuronides has been linked with the toxic properties of drugs that contain carboxylic acid moieties. It is now well documented that such metabolites can reach appreciable concentrations in blood. Furthermore, they are labile, undergo hydrolysis and pH-dependent intramolecular acyl migration to isomeric conjugates of glucuronic acid, and may react irreversibly with plasma proteins, tissue proteins, and with nucleic acids. This stable binding causes chemical alterations that are thought to contribute to drug toxicity either through changes in the functional properties of the modified molecules or through antigen formation with subsequent hypersensitivity and other immune reactions. Whereas in vitro data on the toxicity of acyl glucuronides have steadily accumulated, direct evidence for their toxicity in vivo is scarce. Acyl glucuronides display limited stability, which is dependent on pH, temperature, nature of the aglycon, and so on. Therefore, careful sample collection, handling, and storage procedures are critical to ensure generation of reliable pharmacologic and toxicologic data during clinical studies. Acyl glucuronides can be directly quantified in biologic specimens using chromatographic procedures. Their adducts with plasma or cell proteins can be determined after electrophoretic separation, followed by blotting. ELISA techniques have been used to assess the presence of antibodies against acyl glucuronide-protein adducts. This review summarizes the most recent evidence concerning biologic and toxicologic effects of acyl glucuronide metabolites of various drugs and discusses their relevance for drug monitoring. A critical evaluation of the available methodology is included.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12548138     DOI: 10.1097/00007691-200302000-00001

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  24 in total

1.  Simultaneous quantification of free and glucuronidated cannabinoids in human urine by liquid chromatography tandem mass spectrometry.

Authors:  Karl B Scheidweiler; Nathalie A Desrosiers; Marilyn A Huestis
Journal:  Clin Chim Acta       Date:  2012-07-06       Impact factor: 3.786

2.  Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA.

Authors:  Ariane Wohlfarth; Marisol S Castaneto; Mingshe Zhu; Shaokun Pang; Karl B Scheidweiler; Robert Kronstrand; Marilyn A Huestis
Journal:  AAPS J       Date:  2015-02-28       Impact factor: 4.009

Review 3.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

4.  The occurrence of diarrhea not related to the pharmacokinetics of MPA and its metabolites in liver transplant patients.

Authors:  Zhang Wei Xia; Chen Yong Jun; Chen Hao; Chen Bing; Shi Min Min; Xie Jun Jie
Journal:  Eur J Clin Pharmacol       Date:  2010-05-15       Impact factor: 2.953

5.  A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients.

Authors:  Daniel Moj; Hugo Maas; André Schaeftlein; Nina Hanke; José David Gómez-Mantilla; Thorsten Lehr
Journal:  Clin Pharmacokinet       Date:  2019-12       Impact factor: 6.447

6.  Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite.

Authors:  Miroslav Dostalek; Michael H Court; Suwagmani Hazarika; Fatemeh Akhlaghi
Journal:  Drug Metab Dispos       Date:  2010-12-01       Impact factor: 3.922

7.  A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients.

Authors:  Nicolas Picard; Aurélie Prémaud; Annick Rousseau; Yannick Le Meur; Pierre Marquet
Journal:  Br J Clin Pharmacol       Date:  2006-10       Impact factor: 4.335

8.  Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search.

Authors:  Ariane Wohlfarth; Karl B Scheidweiler; Xiaohong Chen; Hua-fen Liu; Marilyn A Huestis
Journal:  Anal Chem       Date:  2013-03-18       Impact factor: 6.986

9.  The human UGT1A3 enzyme conjugates norursodeoxycholic acid into a C23-ester glucuronide in the liver.

Authors:  Jocelyn Trottier; Diala El Husseini; Martin Perreault; Sophie Pâquet; Patrick Caron; Sylvie Bourassa; Mélanie Verreault; Ted T Inaba; Guy G Poirier; Alain Bélanger; Chantal Guillemette; Michael Trauner; Olivier Barbier
Journal:  J Biol Chem       Date:  2009-11-04       Impact factor: 5.157

10.  In vitro stability of free and glucuronidated cannabinoids in urine following controlled smoked cannabis.

Authors:  Nathalie A Desrosiers; Dayong Lee; Karl B Scheidweiler; Marta Concheiro-Guisan; David A Gorelick; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-12-01       Impact factor: 4.142

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.